ES2168312T3 - Utilizacion de angiotensina iii y sus analogos para la reparacion tisular. - Google Patents

Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.

Info

Publication number
ES2168312T3
ES2168312T3 ES94928150T ES94928150T ES2168312T3 ES 2168312 T3 ES2168312 T3 ES 2168312T3 ES 94928150 T ES94928150 T ES 94928150T ES 94928150 T ES94928150 T ES 94928150T ES 2168312 T3 ES2168312 T3 ES 2168312T3
Authority
ES
Spain
Prior art keywords
analogs
tissular
repair
angiotensin iii
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94928150T
Other languages
English (en)
Inventor
Kathleen Elizabeth Rodgers
Gere Stodder Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2168312T3 publication Critical patent/ES2168312T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ANGIOTENSINA III Y ANALOGOS DE LA MISMA SON UTILES EN LA ACELERACION DE CICATRIZACION DE HERIDAS. ESTOS ANALOGOS FORMAN LA BASE DE COMPOSICIONES UTILES PARA ACELERAR LA CICATRIZACION DE HERIDAS, EN LAS QUE EL AGENTE ACTIVO ESTA PRESENTE EN UNA CANTIDAD EFECTIVA PARA ACELERAR LA CICATRIZACION DE HERIDAS. PREFERIBLEMENTE, LAS COMPOSICIONES ESTAN EN FORMA DE SOLUCIONES MATRICALES O MICELARES.
ES94928150T 1993-09-24 1994-09-19 Utilizacion de angiotensina iii y sus analogos para la reparacion tisular. Expired - Lifetime ES2168312T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12636893A 1993-09-24 1993-09-24

Publications (1)

Publication Number Publication Date
ES2168312T3 true ES2168312T3 (es) 2002-06-16

Family

ID=22424455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94928150T Expired - Lifetime ES2168312T3 (es) 1993-09-24 1994-09-19 Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.

Country Status (13)

Country Link
US (1) US5629292A (es)
EP (1) EP0730465B1 (es)
JP (1) JPH09502977A (es)
AT (1) ATE210677T1 (es)
AU (1) AU706333B2 (es)
CA (1) CA2172493C (es)
DE (1) DE69429450T2 (es)
DK (1) DK0730465T3 (es)
ES (1) ES2168312T3 (es)
PT (1) PT730465E (es)
TW (1) TW311088B (es)
WO (1) WO1995008337A1 (es)
ZA (1) ZA947338B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
AU758319B2 (en) * 1994-11-14 2003-03-20 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
MY121607A (en) * 1995-07-10 2006-02-28 Hyundai Curitel Inc Grid moving method of object image and apparatus using the same and compaction/motion estimation method using the same and apparatus thereof
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
EP1410801B1 (en) 1997-01-28 2013-04-10 University Of Southern California Method for promoting hematopoietic cell proliferation and differentiation
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1998033813A2 (en) * 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US6197751B1 (en) 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
CA2310852A1 (en) * 1997-11-26 1999-06-03 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
CA2315266C (en) 1997-12-12 2004-08-10 University Of Southern California Wound healing compositions
US6239109B1 (en) 1998-02-09 2001-05-29 University Of Southern California Method of promoting erythropoiesis
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
WO1999046285A2 (en) 1998-03-11 1999-09-16 University Of Southern California Method of promoting production of living tissue equivalents
AU752041B2 (en) * 1998-04-09 2002-09-05 University Of Southern California Methods for treatment and prevention of infections
AU759285B2 (en) 1998-05-11 2003-04-10 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
EP1094829B8 (en) 1998-07-13 2004-09-22 University Of Southern California Methods for accelerating bone and cartilage growth and repair
EP1105149A1 (en) 1998-08-13 2001-06-13 University Of Southern California Methods to increase blood flow to ischemic tissue
ATE286511T1 (de) * 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
CA2430010A1 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US7122523B2 (en) * 2001-05-01 2006-10-17 University Of Southern California Methods for inhibiting tumor cell proliferation
JP2010538997A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 肺炎連鎖球菌感染の治療における治療剤としての、フィブリノゲン受容体アンタゴニストおよび／またはゴナドトロピン放出ペプチドの使用
JP5385283B2 (ja) * 2007-09-11 2014-01-08 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのウロコルチンおよび副腎皮質刺激ホルモン放出因子の使用
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100075439A (ko) * 2007-09-11 2010-07-02 몬도바이오테크 래보래토리즈 아게 치료제로서의 감마 1 ｍｓｈ 단독 또는 펜타가스트린과의 배합물
ES2371521T3 (es) * 2007-09-11 2012-01-04 Mondobiotech Laboratories Ag Uso del péptido phpfhlfvy (inhibidor de renina) como agente terapéutico.
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
AU2009333883B2 (en) 2008-12-29 2015-05-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
EA026440B1 (ru) 2011-02-02 2017-04-28 Университи Оф Сатерн Калифорния Способ лечения диабетической язвы стопы
EA201491455A1 (ru) 2012-01-31 2015-01-30 Тревена, Инк. ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CA2916701A1 (en) 2013-07-03 2015-01-08 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
AU2015213777A1 (en) 2014-02-07 2016-09-22 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
JP2017518290A (ja) 2014-05-19 2017-07-06 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． β−アレスチンエフェクターの合成
EP3171886A4 (en) 2014-07-21 2018-01-24 The Arizona Board of Regents On Behalf of the University of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US10960045B2 (en) * 2015-10-14 2021-03-30 Constant Therapeutics Llc Methods and compositions for the treatment of epidermolysis bullosa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886134A (en) * 1970-03-09 1975-05-27 Morton Norwich Products Inc Analogues of angiotensin II
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair

Also Published As

Publication number Publication date
US5629292A (en) 1997-05-13
DK0730465T3 (da) 2002-04-08
JPH09502977A (ja) 1997-03-25
ATE210677T1 (de) 2001-12-15
TW311088B (es) 1997-07-21
EP0730465A1 (en) 1996-09-11
EP0730465A4 (en) 1997-11-12
CA2172493C (en) 2003-09-16
PT730465E (pt) 2002-06-28
ZA947338B (en) 1995-05-10
WO1995008337A1 (en) 1995-03-30
CA2172493A1 (en) 1995-03-30
AU706333B2 (en) 1999-06-17
DE69429450T2 (de) 2002-07-25
EP0730465B1 (en) 2001-12-12
AU7730294A (en) 1995-04-10
DE69429450D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
ES2168312T3 (es) Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
DE69435301D1 (de) Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
MX9703609A (es) Uso de fragmentos de angiotensina ii y analogos de la misma para la preparacion de composiciones en la preparacion de tejido.
BRPI0513460A (pt) composição aquosa suave apropriada para a limpeza do cabelo e da pele
ATE468889T1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
GT199600026A (es) Isotiazolonas
CY1106064T1 (el) Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση
ES2110003T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
PE30298A1 (es) Inhibidores de metaloproteasas de matriz
PE27891A1 (es) Metodo y composicion para humectar tejidos
AR004026A1 (es) Procedimiento de tintura por oxidacion de las fibras queratinicas, una composicion tintorea empleada en dicho procedimiento y dispositivo de varioscompartimentos que comprende la composicion tintorea y la composicion oxidante empleadas en dicho procedimiento.
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
BRPI0413588A (pt) sistema de branqueamento de dentes, método de branqueamento da superfìcie de um dente, e, kit de branqueamento de dentes
BRPI0411690A (pt) composição,processos para o tratamento das fibras queratìnicas, dispositivo com vários compartimentos e uso da composição
ES2059786T3 (es) Composicion blanqueante.
MX9305354A (es) Detergente liquido o en forma de gel para el lavado de vajilla que contiene alquil etoxi carboxilato, iones divalentes y alquilpolietoxipolicarboxilato.
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
BR0117149A (pt) Uso de um copolìmero para produzir uma forma farmacêutica contendo um peptìdio ou proteìna como agente ativo
ES2082894T3 (es) Dihidropirido(4,3-d)pirimidinas 4-sustituidas como analgesicos y agentes antiinflamatorios topicos para el tratamiento de enfermedades de la piel.
ES2159013T3 (es) Forma farmaceutica para la liberacion de colagenasa en heridas y procedimiento para su elaboracion.
ES2129135T3 (es) Composiciones limpiadoras que contienen un alcanoato como acondicionador.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730465

Country of ref document: ES